VS tumours in individuals with NF2 SWN are heterogeneous both clinically and therapeutically, and as we have demonstrated this heterogeneity extends to the histopathological, cellular and spatial levels, highlighting potential for improved patient stratification and better management of the disease. The gene discussed is NF2; the disease is neoplasm.